Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Varun Monga

Showing results (71-80 of 88) with videos related to

Pageof 9
Sort By:
Journal of Adolescent and Young Adult Oncology|March 23, 2022
Sexual Dysfunction Among Adolescent and Young Adult Men Diagnosed with CancerQuinn Carroll Rainer, Justin Michael Dubin, Navin Chakravarthy Balaji, et al.
The Lancet. Oncology|January 19, 2026
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trialVarun Monga, Scott Okuno, Brian Van Tine, et al.
JCO Oncology Practice|December 14, 2021
Use of Communication Technology to Improve Clinical Trial Participation in Adolescents and Young Adults With Cancer: Consensus Statement From the Children's Oncology Group Adolescent and Young Adult Responsible Investigator NetworkViswatej Avutu, Varun Monga, Nupur Mittal, et al.
Frontiers in Immunology|September 8, 2022
Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapyAmira Zaher, Laura M Stephens, Ann M Miller, et al.
Genes|November 11, 2022
The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective AnalysisLawrence Liu, Carina Dehner, Nikhil Grandhi, et al.
Neuro-Oncology|May 31, 2022
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trialMacarena I de la Fuente, Howard Colman, Mark Rosenthal, et al.
Journal for Immunotherapy of Cancer|July 31, 2021
Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trialVarun Monga, Benjamin J Miller, Munir Tanas, et al.
The New England Journal of Medicine|June 3, 2026
Targeting of Wnt-β-Catenin Pathway in Recurrent AmeloblastomaSamuel J Klempner, Moh'd Khushman, Kyriakos P Papadopoulos, et al.
JCO Oncology Advances|May 7, 2025
Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2 Macrophage ActivationGulam A Manji, Liam J Stanton, Angela C Hirbe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2023
CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor RegressionJordan L Kohlmeyer, Joshua J Lingo, Courtney A Kaemmer, et al.
Pageof 9

Showing results (71-80 of 88) with videos related to

Sort By:
Pageof 9
Journal of Adolescent and Young Adult Oncology|March 23, 2022
Sexual Dysfunction Among Adolescent and Young Adult Men Diagnosed with CancerQuinn Carroll Rainer, Justin Michael Dubin, Navin Chakravarthy Balaji, et al.
The Lancet. Oncology|January 19, 2026
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trialVarun Monga, Scott Okuno, Brian Van Tine, et al.
JCO Oncology Practice|December 14, 2021
Use of Communication Technology to Improve Clinical Trial Participation in Adolescents and Young Adults With Cancer: Consensus Statement From the Children's Oncology Group Adolescent and Young Adult Responsible Investigator NetworkViswatej Avutu, Varun Monga, Nupur Mittal, et al.
Frontiers in Immunology|September 8, 2022
Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapyAmira Zaher, Laura M Stephens, Ann M Miller, et al.
Genes|November 11, 2022
The Impact of TSC-1 and -2 Mutations on Response to Therapy in Malignant PEComa: A Multicenter Retrospective AnalysisLawrence Liu, Carina Dehner, Nikhil Grandhi, et al.
Neuro-Oncology|May 31, 2022
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trialMacarena I de la Fuente, Howard Colman, Mark Rosenthal, et al.
Journal for Immunotherapy of Cancer|July 31, 2021
Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trialVarun Monga, Benjamin J Miller, Munir Tanas, et al.
The New England Journal of Medicine|June 3, 2026
Targeting of Wnt-β-Catenin Pathway in Recurrent AmeloblastomaSamuel J Klempner, Moh'd Khushman, Kyriakos P Papadopoulos, et al.
JCO Oncology Advances|May 7, 2025
Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2 Macrophage ActivationGulam A Manji, Liam J Stanton, Angela C Hirbe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2023
CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor RegressionJordan L Kohlmeyer, Joshua J Lingo, Courtney A Kaemmer, et al.
Pageof 9